NI company Randox bucks the trend in providing forensic services to GB police forces

Home - Archives for January 2015

NI company Randox bucks the trend in providing forensic services to GB police forces

Leading forensic toxicology company, Randox, are riding high despite a recent National Audit Office report which raised concerns about a reducing marketplace for private forensic services.

The Co. Antrim-based company are bucking the trend and growing market-share, and in 2014 provided forensic services to all 43 police forces across England and Wales.

Recently the NAO raised concerns that a shrinking private forensic marketplace will result in reduced capacity, and detrimentally impact the judicial process. 

At present UK police forces can either conduct forensic toxicology testing in-house, where such laboratory facilities exist, or outsource the work to one of ten fully-accredited service providers – including Randox – through the National Forensic Framework procurement process.

Under the Framework, all private forensic service providers must be fully accredited, which is a costly process but ensures that rigorous practices are upheld. The NAO highlights that the Forensic Regulator does not have powers to force police labs to comply with accreditation standards. 

As police budgets are cut and more forensics are brought in-house, expenditure on private sector forensic services have declined significantly, to around £60m a year. 

NAO highlights a growing concern in the industry that if forensic services continue to move in-house this will force some private operators to pull out of the market. 

Gary McCutcheon, Manager of Randox Testing Services said: 

“Randox is extremely proud to be one of only 10 forensic providers on the National Forensic Framework: all 43 police services in England and Wales have used Randox’s forensic toxicology services. The fact we are now an established provider, meeting and exceeding standards, means we are a major player and puts us in a strong position going forward.

“Having achieved considerable success in GB police forces we are in a strong position, when circumstances allow, to provide the same first class services and considerable cost savings to forensic toxicology users in Northern Ireland.”


Randox Strengthens Regional Commitment with Expansion Plans in County Antrim

  • £161m investment including £29m capital project and creation of 540 jobs
  •  Next generation medical diagnostics manufacturing facility
  • World leading R&D into conditions such as cancer, stroke, heart disease, neurodegenerative disorders, sepsis, STIs, aspirin resistance and respiratory infections
  • Randox Science Park to complement Randox Teoranta’s #Dungloe2020 expansion

“This investment and expansion in County Antrim, combined with our plans for Randox Teoranta in Donegal, provides us with an extraordinary regional footprint, which will be the foundation of our global development and which will fuel our endeavours to improve health worldwide…”

Global medical diagnostics company Randox, has unveiled its plans for a futuristic manufacturing and R&D facility in County Antrim. The £161 million project, which includes a £29 million capital investment for the redevelopment of the site, will lead to the creation of 540 high value job opportunities, over the next four years.

Randox which leads in the research, development and manufacture of pioneering medical tests and cutting edge diagnostic equipment, recently revealed its plans to upgrade Randox Teoranta, in Donegal with a €25m investment, which would also see employment at the Dungloe site increase from 66 to 540 by 2020. 

The award-winning biotechnology firm, with headquarters in Crumlin, County Antrim, recently purchased a 47 acre site in Antrim, which will be redeveloped to house a new centre of manufacturing and R&D, named Randox Science Park. 

Randox Science Park, will complement Randox manufacturing operations in County Donegal, Manchester, India and the USA. Randox has a range of 2000 products, including advanced diagnostic tests, quality control sera, analysers and the company’s revolutionary BioChip Array Technology; the vast majority will be produced between Co Donegal and Co Antrim.

This considerable investment will accelerate the development of new products into a wide range of clinical needs, such as various cancer, stroke, heart disease and neurodegenerative disorders, through more efficient, high specification manufacturing and the provision of state-of-the-art R&D laboratories. 

The site will also feature a Transformative Healthcare Centre from the Randox Health division; giving the public direct access to Randox’s ground-breaking diagnostic tests, as well as offering private GP appointments and specialist clinics, run by some of the North of Ireland’s chief medical consultants.

At a launch event today, Randox showcased its plans for Randox Science Park. Guests including Northern Ireland’s First Minister, Peter Robinson, Deputy First Minister, Martin McGuinness and Enterprise Minister, Arlene Foster, were briefed on the company’s impact on global health and vision for the future.

Speaking at the event, Randox Managing Director, Dr Peter FitzGerald said: 

“The creation of Randox Science Park is fundamental to Randox meeting the health challenges facing populations across the world. We are an innovation led company, focusing more than 30 years of skills and experience on delivering accurate, rapid and quality diagnostics across a range of clinical disciplines; from stroke and heart disease, to cancer, neurodegenerative disorders, respiratory infections and so on. We must continue innovating, through our people, through our knowledge and through our technology; Randox Science Park gives us the platform we need to do this.

“This investment and expansion in County Antrim, combined with our plans for Randox Teoranta in Donegal, provides us with an extraordinary regional footprint, which will be the foundation of our global development and which will fuel our determination to improve health worldwide. It is about the future of diagnostic medicine; we are beginning 2015 as we mean to continue.”

Meanwhile the first recruitment drive for the #Dungloe2020 expansion of Randox Teoranta, which has backing from Údarás na Gaeltachta continues. The company is keen to hear from those in life sciences, medical device engineering and software; with a particular focus on software developers and testers, embedded software engineers, those with backgrounds in mechanical design as well as electronic & electrical engineers. For more information on the world-class career opportunities available at Randox Teoranta please email recruitment@randoxteoranta.com


Randox puts British Biotechnology on World Map with New Randox Science Park

  •  £161m investment including £29m capital project and creation of 540 jobs
  • Next generation medical diagnostics manufacturing facility
  • World leading R&D into conditions such as cancer, stroke, heart disease, neurodegenerative disorders, STIs, aspirin resistance, sepsis and respiratory infections

“This investment and expansion reinforces our dedication to improving health worldwide…”

Global medical diagnostics company Randox, has unveiled its plans for a futuristic manufacturing and R&D facility in the UK. The £161 million project, which includes a £29 million capital investment for the redevelopment of the site, will accelerate the development of new products into a wide range of clinical needs, such as various cancers, stroke, heart disease and neurodegenerative disorders, through more efficient, high specification manufacturing and the provision of state-of-the-art R&D laboratories. 

Randox leads in the research, development and manufacture of pioneering medical tests and cutting edge diagnostic equipment, with customers in clinical, toxicology, veterinary and food safety markets in more than 145 countries.

The award-winning biotechnology firm, with headquarters in Crumlin, County Antrim, recently purchased the former British Army base at Massereene, in Antrim town, which will be redeveloped to house the new centre of manufacturing and R&D, now renamed, Randox Science Park. 

Randox Science Park will become the company’s prime manufacturing site, complementary to its manufacturing operations in Manchester, Republic of Ireland, India and the USA. Randox has a range of more than 2000 products, including advanced diagnostic tests, quality control sera, analysers and the company’s revolutionary BioChip Array Technology; many of which will be produced at this next generation facility.

This considerable investment will also lead to the creation of 540 high value job opportunities, over the next four years.

In addition, the site will feature a Transformative Healthcare Centre from the Randox Health division; giving the public direct access to Randox’s ground-breaking tests, as well as offering private GP appointments and specialist clinics, run by some of the UK’s chief medical consultants.

At a launch event today, Randox showcased its plans for Randox Science Park. Guests including Northern Ireland’s First Minister, Peter Robinson, Deputy First Minister, Martin McGuinness and Enterprise Minister, Arlene Foster, were briefed on the company’s impact on global health and vision for the future.

Speaking at the event, Randox Managing Director, Dr Peter FitzGerald said: 

“The creation of Randox Science Park is fundamental to Randox meeting the health challenges facing populations across the world. We are an innovation led company, focusing more than 30 years of skills and experience on delivering accurate, rapid and quality diagnostics across a range of clinical disciplines; from stroke and heart disease, to cancer, neurodegenerative disorders, respiratory infections and so on. We must continue innovating, through our people, through our knowledge and through our technology; Randox Science Park gives us the platform we need to do this.

“Randox innovation underpins our achievements, allows us to diversify, allows us to target fresh markets and fuels our exports and Randox Science Park will be at its core. This investment and expansion reinforces our dedication to improving health worldwide and our commitment to the UK economy. It is about the future of diagnostic medicine, we are beginning 2015 as we mean to continue.”

The expansion includes the creation of manufacturing, scientific and engineering opportunities on a major scale, as well as business support posts; the investment will also grow Randox’s sales and marketing capabilities. In addition, the 540 new jobs, with an average salary of £30k per year will generate £16.2 million in annual salaries, representing a significant boost to the UK economy. 

The company said it was already engaging with universities across the UK, to access high calibre graduates for the world class opportunities at Randox Science Park.

Regional development agency, Invest Northern Ireland is supporting the £29m Randox capital redevelopment of the site, with an investment of £4.7 million.


Vote Randox as UK National Champion in the European Business Awards 2015

Leading clinical diagnostics firm Randox Laboratories goes head to head with some of the biggest brands in the UK, as it competes for the title of ‘National UK Champion’ in the European Business Awards 2015.

Randox, having already faced stiff competition from across the UK to be shortlisted as a National Champion, will now face the public vote and are asking you to put health at the frontline by supporting them.

Randox will be judged by the public from a company video which gives a powerful and inspiring insight into the story of Randox. 

From its headquarters in Crumlin Co Antrim, Randox has grown into an international success story, at the frontline of improving health in conditions such as stroke, dementia, diabetes, heart disease, STI’s and respiratory infections through earlier and more accurate diagnosis. 

Every year a staggering 350 million people – 5% of the world’s population – are diagnosed with Randox products. Randox supplies 10% of the world’s cholesterol tests, and 8% of all clinical chemistry tests undertaken globally: the chances are if you’ve ever had blood taken by a doctor it’s been assessed using a Randox product. 

Randox aren’t standing still: driven by innovation and a commitment to saving lives, Randox currently has more clinical diagnostic tests in development than any other company in the world.

To watch Randox’s video and cast your vote go to www.businessawardseurope.com (or click here.). 

Why vote for Randox? Dr Peter Fitzgerald, Managing Director of Randox says: 

“Randox’s key driver is to save lives. Our raison d‘etre is to improve health not just here in Northern Ireland but right across the world. Our success is built on world-class, innovative products which enable earlier, more accurate diagnosis. In doing so we improve the quality of life, enhance the efficiency of healthcare and save lives, globally.”

Randox will compete against other UK shortlisted Champions for the public vote. The company with the most votes will be named the UK’s ‘National Public Champion’ on 3rd March 2015. From this, National Champions will have the opportunity to compete with winners from across Europe to earn the highly acclaimed title of ‘European Public Champion’ at a glittering Awards Gala event in May 2015.

For more information on the European Business Awards, please visit www.businessawardseurope.com or Randox atwww.randox.com.


Clot-busting drug doesn’t work for 1-in-4 patients – calls for aspirin resistance screening

  • Millions prescribed aspirin to combat blood clotting – but it doesn’t work for 25% of patients
  • Those who test positive at ‘significantly’ increased risk of heart attack and stroke
  • Countless lives could be saved by new £10 Urine test created by Randox to identify aspirin resistant patients

An aspirin a day may not necessarily keep the doctor away, especially if you are among the 1-in 4 people in Britain resistant to the beneficial effects of the ‘wonder drug.

A small dose of aspirin is taken by millions across Britain and around the world to thin the blood, in an attempt to reduce the risk of heart attack and stroke, but major clinical studies have shown that for 1-in-4 aspirin is ineffective. Validated research has also revealed that the risk of having a heart attack and indeed dying from a cardiovascular event is significantly higher in aspirin resistant patients.

NOT A SILVER BULLET

One of the powerful effects of aspirin is that it inhibits the production of a blood clotting chemical called thromboxane, and as such, it is widely prescribed for the prevention of cardio vascular disease; however the blood thinning properties of aspirin do not work for everybody. In aspirin resistant patients, blood thinning is poor, therefore there is a greater likelihood of clots forming in arteries which are narrowed by fatty and fibrous plaques resulting in heart attack and stroke.

Responding to the problem, scientists at UK Biotechnology Company Randox have developed a new test for aspirin resistance, as Managing Director Dr Peter FitzGerald explains:

“We are faced with the fact that thousands of patients are at increased risk because they are not getting the benefits from their aspirin treatment. Some people have genetic resistance to aspirin, but high cholesterol, diabetes and pre-diabetes (affecting an estimated 1-in-3 people In England) may significantly contribute to the poor aspirin response. Aspirin effectiveness can also be reduced by non-steroidal anti-inflammatory drugs. To make sure these patients get the right treatment, we have developed a simple, £10 urine test, which can detect if a person is responding to their daily aspirin therapy.”

Dr Paul RJ Ames, Consultant in Haemostasis & Thrombosis at St George’s Hospital, London, who has been working with the new test, believes it could have a significant impact on the health of hundreds of thousands of patients in the UK and is calling for doctors to take aspirin resistance seriously: 

“Doctors need to realise that aspirin, the cornerstone of much cardiac therapy is not working for up to 25% of those taking it! Then there are the side effects such as ulcers to consider. Why should you continue to take something that actually isn’t doing any good?! It is also worrying that aspirin resistant patients are twice as likely to suffer a heart attack and almost four times more likely to suffer cardiovascular death than those who are responsive. This increased risk has been clinically validated in internationally recognised research and frontline care must take this knowledge into account. We need to begin testing for aspirin resistance, so that we can identify patients who need alternative treatments, ultimately reducing their risk of heart attack and stroke.”

INCREASED RISK OF DEATH

A ‘meta-analysis’ (summary of 20 studies) published in the British Medical Journal, tracked almost 3000 patients with cardiovascular disease. They were tested and 28% (810 patients) were found to be aspirin resistant. The researchers discovered that 41% of the aspirin resistant patients had a CVD related event, 39.4% of them experienced Acute Coronary Syndrome and 5.7% died. The study concluded that aspirin resistant patients are at a much greater risk of serious cardiovascular disease compared to patients who are sensitive to aspirin.

Meanwhile a major Canadian research project which studied 976 aspirin treated patients, found that those who were aspirin resistant were twice as likely to have a heart attack, and worryingly, almost 4 times at greater risk of cardiovascular death. 

According to the British Heart Foundation, there are more than a quarter of a million heart attacks and strokes in the UK each year, it is not yet known how many of these were suffered by aspirin resistant patients, but it is evident that aspirin, the basis of treatment for millions at cardiovascular risk, is not a one-pill-wonder.

For the first time, a test is available which can rapidly and accurately identify aspirin resistance, a breakthrough in individual patient management; with the potential to revolutionise health care for those with cardiovascular risk.


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Clinical Laboratory Survey